Piramal Diagnostics In Sell-off Talks With SRL; 20 Percent Annual Growth Draws Big Investors To India
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - After the company has vehemently denied rumors on the topic in the past, strong speculation has resurfaced that India's Piramal Diagnostics is close to selling off its diagnostics business to Malvinder Singh-controlled SRL - known earlier as Specialty Ranbaxy Laboratories
You may also be interested in...
With Oxygen Healthcare Buy, India's Piramal Healthcare Breathes More Life Into Its Chemistry Skills
MUMBAI - Flush with $3.72 billion from its much publicized deal struck last year with Abbott Laboratories for its India prescriptions business, Piramal Healthcare is eyeing strategic acquisitions to strengthen its remaining businesses spanning contract research and manufacturing services, OTC drugs and critical care medications
With Oxygen Healthcare Buy, India's Piramal Healthcare Breathes More Life Into Its Chemistry Skills
MUMBAI - Flush with $3.72 billion from its much publicized deal struck last year with Abbott Laboratories for its India prescriptions business, Piramal Healthcare is eyeing strategic acquisitions to strengthen its remaining businesses spanning contract research and manufacturing services, OTC drugs and critical care medications
Indian Healthcare Industry To Zoom Past $14 Billion In The Next Three Years; Quadruple By 2017 - KPMG Report
MUMBAI - The Indian healthcare industry is estimated to double in value by 2012 at $14.2 billion and more than quadruple by 2017 from the present levels but healthcare infrastructure over the last decade has not kept pace with growth in population. This was revealed in a report, published by global management and accounting consultant KPMG, which predicts that health infrastructure across all Indian states will grow by an average 5.8 percent per annum